Several studies have shown that higher levels of FGF-23 are associated with a higher risk of death (Scialla et al., 2014; Charytan et al., 2015).In spite of significant breakthroughs in our understanding and treatment of the CV disease associated with CKD, mortality remains high and identifying new therapeutic targets is of critical importance. The gene discussed is FGF23; the disease is chronic kidney disease.